Evidence map›Paper›PMID 39771608›Full record

ArticlePharmaceutics2024

Vedolizumab Clearance as a Surrogate Marker for Remission in Inflammatory Bowel Disease Patients: Insights from Real-World Pharmacokinetics.

Srđan Marković, Đorđe Kralj, Petar Svorcan, Tamara Knežević Ivanovski, Olga Odanović, Sanja Obradović, Ana Homšek, Marija Jovanović, Rada Savić, Katarina M Vučićević

Abstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Therapeutic Drug Monitoring of Vedolizumab Levels During Maintenance in Inflammatory Bowel Disease (MOVE-IBD).JGH open : an open access journal of gastroenterology and hepatology · 2026
    Article
  2. Article
  3. [Research progress on biologics and therapeutic drug monitoring in pediatric inflammatory bowel disease].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Srđan MarkovićDepartment of Gastroenterology and Hepatology, University Hospital Medical Center "Zvezdara", 11120 Belgrade, Serbia.
Đorđe KraljDepartment of Gastroenterology and Hepatology, University Hospital Medical Center "Zvezdara", 11120 Belgrade, Serbia.ORCID 0009-0005-9153-2153
Petar SvorcanDepartment of Gastroenterology and Hepatology, University Hospital Medical Center "Zvezdara", 11120 Belgrade, Serbia.ORCID 0000-0001-7627-812X
Tamara Knežević IvanovskiDepartment of Gastroenterology and Hepatology, University Hospital Medical Center "Zvezdara", 11120 Belgrade, Serbia.
Olga OdanovićDepartment of Gastroenterology and Hepatology, University Hospital Medical Center "Zvezdara", 11120 Belgrade, Serbia.
Sanja ObradovićDepartment of Laboratory Diagnostics, University Hospital Medical Center "Zvezdara", 11120 Belgrade, Serbia.
Ana HomšekDepartment of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-0127-5538
Marija JovanovićDepartment of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia.
Rada SavićDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94143, USA.
Katarina M VučićevićDepartment of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0001-9676-5785

Funding

Science Fund of the Republic of Serbia 6777
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

clearanceIBDmonoclonal antibodyNONMEMpharmacokineticstherapeutic drug monitoring

Identifiers

PMID39771608
PMCPMC11677246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.